Abstract
BACKGROUND: Awake prone positioning (APP) has been advocated to improve oxygenation and prevent intubation of patients with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). This paper aims to synthesize the available evidence on the efficacy of APP.
METHODS: We performed a systematic review of proportional outcomes from observational studies to compare intubation rate in patients treated with APP or with standard care.
RESULTS: A total of 46 published and 4 unpublished observational studies that included 2,994 subjects were included, of which 921 were managed with APP and 870 were managed with usual care. APP was associated with significant improvement of oxygenation parameters in 381 cases of 19 studies that reported this outcome. Among the 41 studies assessing intubation rates (870 subjects treated with APP and 852 subjects treated with usual care), the intubation rate was 27% (95% CI 19–37%) as compared to 30% (95% CI 20–42%) (P = .71), even when duration of application, use of adjunctive respiratory assist device (high-flow nasal cannula or noninvasive ventilation), and severity of oxygenation deficit were taken into account. There appeared to be a trend toward improved mortality when APP was compared with usual care (11% vs 22%), which was not statistically significant.
CONCLUSIONS: APP was associated with improvement of oxygenation but did not reduce the intubation rate in subjects with acute respiratory failure due to COVID-19. This finding is limited by the high heterogeneity and the observational nature of included studies. Randomized controlled clinical studies are needed to definitively assess whether APP could improve key outcome such as intubation rate and mortality in these patients.
- coronavirus disease 2019
- severe acute respiratory syndrome coronavirus 2
- ARDS
- acute hypoxemic respiratory failure
- high-flow nasal cannula
- awake prone positioning
- noninvasive ventilation
- CPAP
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has led to a sudden surge of hospital admissions for acute hypoxemic respiratory failure. A significant proportion of patients who are hospitalized for COVID-19 fulfills the criteria for the ARDS1 and requires prolonged mechanical ventilation. Prone positioning is one of the few interventions that has been proven to reduce mortality in intubated and mechanically ventilated patients with moderate to severe ARDS.2,3 This effect is likely mediated through a combination of better lung recruitment, reduced ventilation-perfusion mismatch, and prevention of alveolar strain and ventilator-induced lung injury by a more homogenous distribution of pleural pressures throughout the lung parenchyma.4
Groups worldwide have reported on the use of APP in acute hypoxemic respiratory failure due to COVID-19 and showed improvement of oxygenation and reduction of breathing frequency in populations with varying disease severity.5-11 Despite studies reporting outcomes being limited to case series and cohort studies, awake prone positioning (APP) has been widely adopted and included in the guidelines on management of COVID-19 pneumonia without any evidence that improvement of surrogate physiological end points translates into better clinical outcomes, such as reduced incidence of intubation or reduced mortality.
The aim of this systematic review of proportional outcomes from observational studies was to investigate the hypothesis that APP of non-intubated patients with acute hypoxemic respiratory failure due to COVID-19 results in reduced intubation rate. The impact of APP on intubation rate is the primary outcome, and its effects on oxygenation, mortality, and the tolerability of APP are reported as exploratory secondary outcomes. We also explored the impacts of the duration of APP; the severity of the acute hypoxemic respiratory failure; and the type of respiratory support, such as conventional oxygen therapy, high-flow nasal cannula (HFNC), or noninvasive ventilation (NIV), on respiratory parameters, intubation rate, and mortality.
Methods
This study was registered on PROSPERO (CRD42020201947), and the detailed protocol is available (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=201947 Accessed September 28, 2021). Our findings are presented in conformity with the PRISMA guidelines.12
Search Strategy and Study Selection
Two investigators (HH and JL) searched the MEDLINE, Embase, PubMed, Web of Science, Scopus, medRixv, bioRixv, ClinicalTrials.gov, and Wanfang databases for studies published from January 1, 2020, to August 15, 2020, with restrictions to English and Chinese languages. The key words of “prone position*” OR “Pron*” AND “COVID-19” OR “SARS” OR “coronavirus” AND “awake” OR “non-intubated” OR “conscious” were utilized to search literature evaluating APP for subjects with COVID-19. This enabled the identification of cohorts of subjects treated with APP. The key words of “nasal high-flow” OR “HFNC” OR “high-flow nasal cannula” OR “noninvasive ventilation” OR “NIV” OR “continuous positive airway pressure” OR “CPAP” AND “COVID-19” OR “SARS” OR “coronavirus” were used to identify reports of subjects treated with either HFNC or NIV/CPAP, without the use of APP, to be included as a control cohort. Equivalent key words were used for searches in Chinese. Searches were supplemented with examination of reference lists in identified studies and verbal communication with experts.
Studies were included if they met the following criteria: (1) original research reports of COVID-19 subjects and (2) subjects were treated with APP and/or HFNC or NIV or conventional oxygen therapy. The exclusion criteria were (1) languages other than English or Chinese, (2) study protocols, review articles, abstracts, editorials, (3) research on newborns or animals, and (4) reports of fewer than 3 cases.
The investigators then independently parsed through the titles and abstracts of all identified articles and produced a list of potentially relevant papers. The full texts of these papers were then reviewed, and a final list of studies to be included in the meta-analysis was produced. Any disagreements were resolved by consensus.
Data from the articles were extracted by 2 independent teams (HH and JL, BM, and YP) using a standardized data extraction form. Extracted data included the authors, year of study, country, patient characteristics, the type of respiratory support, the details of APP intervention, tolerability, and outcomes. Any disagreements were resolved by consensus in the presence of all 4 investigators.
If the outcomes of intubation rate and mortality were not reported, or if it was not clear whether the subjects received APP and for what duration, the corresponding authors were contacted for clarifications. To enlarge the sample size, and to assess for the possibility of publication bias, unpublished data provided by the investigators’ institutions (BM, JAJ, WZ, DSR) were also included in the meta-analysis. Ethical approval was obtained at each institution prior to data collection.
Preplanned Statistical Analyses
The primary outcome was the in-hospital intubation rate. The proportion of physiological responders to APP and the in-hospital mortality were reported as secondary outcomes. In conformity with established custom in the ARDS literature, responders were defined by an increase of 
/
ratio ≥ 20%.13 When the 
/
was not reported, an increase of 
/
ratio ≥ 20% was considered as a response given the linear relationship between the 2 ratios.14,15 In-hospital mortality was reported as an exploratory secondary outcome, as it is a complex outcome that is modulated by multiple individual and population-level confounders.
For dichotomous outcomes, we pooled proportions using a logit transformation with 95% CI. We assessed statistical heterogeneity by visual inspection of the forest plots and by calculating the Q and I2 statistics, which were interpreted according to conventional thresholds. For all analyses, we implemented random-effects models with inverse variance weighting, providing that at least 3 studies were available.
Potential sources of heterogeneity or inconsistency included baseline disease severity in terms of 
/
at the initiation of therapy, duration of APP, the timing of APP initiation, and the type of respiratory support (ie, conventional oxygen therapy, HFNC, NIV). We investigated the distributions of these characteristics across groups and studies.
We prespecified 3 characteristics in the protocol to be subject to subgroup analyses on the probability of intubation and mortality. When the information was available, we limited the analysis to the studies with 
/
< 150 mm Hg versus ≥ 150 mm Hg and according to respiratory support devices (HFNC vs CPAP/NIV). The cutoff value of 
/
< 150 mm Hg was based on the previously described survival benefit when these subjects were managed with intubation, as compared to a noninvasive strategy with a high chance of failure.16 The third subgroup analysis was limited to studies in the group of APP, in which we analyzed the relationship between APP duration and the probability of intubation and mortality. Up to 0.6 statistically significant interaction tests (P < .05) would be expected on chance alone.
We did not formally assess bias of included studies, as all of them were observational and inherently highly biased. We did not produce a funnel plot, as this method is inaccurate for meta-analyses of proportion studies.17
Post Hoc Comparator Groups
While collecting data, and before carrying out any analyses, we realized that only a minority of identified papers reported on pure populations in which either all subjects were subjected to APP or none was. We, therefore, decided to group subjects into 3 groups a priori: (1) APP when all subjects were proned, (2) some APP when some (at least 10%) but not all subjects were proned, and (3) no APP when no subjects were proned (< 10%). Papers that focused on APP were classified as APP, regardless of the number or proportion of subjects that was able to remain in prone position (PP). We compared subjects treated with APP (group 1) with those not treated with APP (group 3), and we finally reported the P value associated with the test for subgroup differences between group 1 and group 3. All analyses were performed in R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) with the help of meta package.
Results
Our search strategy identified 173 publications on the subject of APP (Fig. E1 in the online supplement, see the related supplementary materials at http://www.rcjournal.com) and 271 papers on the subject of noninvasive oxygenation modalities (Fig. E2 in the online supplement, see the related supplementary materials at http://www.rcjournal.com) in severe COVID-19. Thus, a total of 444 potentially relevant publications were identified, and 440 were screened for inclusion after removal of duplicates (Fig. 1). After full-text review, 46 published studies5-7,9,11,18-57 and data from 4 unpublished data sets were included in the final review, with a combined 2,994 subjects: 921 treated with APP, 870 treated without APP, and a group of 1,203 in whom a significant proportion was treated with APP (Fig. 1, Table 1, and Tables E1 and E2 in the online supplement, see the related supplementary materials at http://www.rcjournal.com). Clarifications and supplementary materials were obtained from 18 corresponding authors.
Flow chart. *One paper reported on both subgroups and is thus counted twice.
Basic Characteristics and Main Results for Studies With Awake Prone Positioning
Detailed Information About the Studies That Implemented Awake Prone Positioning
Physiological Response to Awake Prone Positioning
Nineteen studies (n = 381) reported on the physiological responses to APP. APP resulted in improved 
or 
in all 13 studies (n = 271) that reported on changes in oxygenation.
Ten studies (n = 198) reported on changes in the 
/
ratio; of them, 9 (n = 192) reported significant improvement in 
/
ratios with APP. Mean improvement was greater than our predefined threshold of ≥ 20% in all 7 studies in which changes of 
/
ratios were reported in sufficient detail. In 3 studies (n = 72), the improvement of the 
/
ratio was sustained even after the subjects returned to the supine position31,34,35; one study (n = 46) demonstrated sustained improvement in only 50% of subjects11; and in another report (n = 26), improvement of 
/
was lost after returning to supine position.32
Reduction of breathing frequency with APP was demonstrated in 5 studies (n = 90)7,18,29,30 but not in 2 other studies (n = 34).23,34 Finally, significantly reduced 
was demonstrated only in a single small study (n = 9)25, whereas no changes in 
were observed in a larger report (n = 46).11
Probability of Intubation With Awake Prone Positioning
Data on intubation rate were available for 870 subjects treated with APP (23 published studies, n = 717; 2 unpublished studies, n = 153) and for 852 subjects treated with HFNC or CPAP or NIV without APP (16 published studies, n = 645; 2 unpublished studies, n = 207). In the APP group, 27% (95% CI 19–37%) required intubation and mechanical ventilation, as compared to 30% (95% CI 20–42%) in the control group (Fig. 2). This difference was not statistically significant (P = .71). Subgroup analyses, with stratification according to the duration of APP (< 4 h daily vs ≥ 4 h daily), the device (HFNC vs CPAP vs NIV), and the severity of the ARDS (
/
< 150 mm Hg vs 
/
≥ 150 mm Hg), did not demonstrate any significant difference in intubation rate between subjects who were treated with APP and those who were not (Fig. 3).
Association between awake prone positioning and intubation in each report and overall. A meta-analysis of pooled proportion demonstrating the intubation rate for studies describing subjects who did or did not undergo prone positioning.
Association between awake prone positioning and intubation within subgroups defined by the duration of proning, the type of respiratory support device, and the 
/
ratio at enrollment. A meta-analysis of pooled proportion of intubation for studies reporting time spent in prone position (< or > 4 h), oxygen delivery device (HFNC, CPAP), and degree of hypoxemia (P/F < or > 150 mm Hg) for studies describing subjects who did not undergo prone positioning and studies that reported in subjects who underwent prone positioning. HFNC = high-flow nasal cannula, PP = prone position, NIV= noninvasive ventilation, P/F = 
/
ratio.
Probability of Death With Awake Prone Positioning
Mortality data were available for 767 subjects treated with APP (18 published studies, n = 614; 2 unpublished studies, n = 153) and for 761 subjects treated with HFNC or CPAP or NIV without APP (12 published studies, n = 554; 2 unpublished studies, n = 207). The mortality rate was 11% (95% CI 6–20%) in subjects treated with APP, as compared to 22% (95% CI 13–36%) in subjects treated with usual care (Fig. 4). This difference was not statistically significant (P = .10). Outcomes were highly heterogeneous between studies, and subgroup analyses did not demonstrate any significant differences in mortality across predetermined subgroups (Fig. 5) and did not identify a subgroup in which APP was associated with statistically significant reduction of mortality.
Association between awake prone positioning and mortality in each report and overall. A meta-analysis of pooled proportion demonstrating the intubation rate for studies describing subjects who did or did not undergo prone positioning.
Association between awake prone positioning and mortality, within subgroups defined by the duration of proning, the type of respiratory support device, and the 
/
at enrollment. A meta-analysis of pooled proportion of mortality for studies reporting time spent in prone position (< or > 4 h), oxygen delivery device (HFNC, CPAP), and degree of hypoxemia (P/F < or > 150 mm Hg) for studies describing subjects who did not undergo prone positioning and studies that reported in subjects who underwent prone positioning. HFNC = high-flow nasal cannula, PP = prone position, NIV = noninvasive ventilation, P/F = 
/
ratio.
Tolerability and Comfort of Awake Prone Positioning
Fifteen studies reported subjects’ tolerability to APP, varying from 47–100%. Eight papers reported on subjects’ discomfort while in PP, including back pain, dyspnea, and general discomfort. The daily duration of APP was reported in 17 papers (n = 366). In 9 papers (n = 201), subjects tolerated APP for < 4 h daily. A single paper reported on a cohort of 55 subjects who were able to achieve APP for more than 16 h daily.36
Discussion
Our systematic review of proportional outcomes from observational studies demonstrated that APP improved oxygenation but did not show benefit for the frequency of intubation or mortality in subjects with acute hypoxemic respiratory failure secondary to COVID-19. The main strength of our study was that it was the first report focused on effect of APP on intubation rate with a comparison with the data from population treated with usual care during the similar time period within the first wave of pandemic. Our study also had a large sample size, with a total of 921 subjects treated with APP.
We found that APP improved oxygenation parameters, and this improvement was sustained even after subjects returned to the supine position in 3 studies.31,34,35 APP was also associated with reduced breathing frequency, and good tolerability was reported with the use of various modalities of respiratory support, including conventional oxygen therapy, HFNC, and CPAP or NIV that was delivered through either a helmet or full face mask. Improvement in oxygenation with APP can be explained by the correction of ventilation-perfusion mismatch,8 better lung recruitment, and reduction of alveolar strain.4 However, improvements in oxygenation do not guarantee better clinical outcomes. For instance, improvements of 
/
ratio do not correlate with mortality in intubated patients subjected to prone positioning.58 More physiological and clinical studies are needed to delineate the relationship between improvement of oxygenation parameters and clinical outcomes in patients with COVID-19.
Contrary to previous reports,24,59 we did not find that APP reduced intubation rates. Several reasons can be advanced to explain this lack of efficacy. First, intubation criteria were not uniformly defined across studies and involved the treating physician’s subjective judgment. During the pandemic, the recommended respiratory support strategies evolved from early aggressive intubation to strategies of respiratory support designed to prevent intubation.5,44,60-62 Second, the timing of APP initiation, either as an adjunctive (early) or rescue (late) therapy, may influence intubation rate. The use of APP at an early stage (
/
ratio > 150 mm Hg) may be better tolerated, result in better oxygenation, and protect patients from self-induced lung injury and thus prevent further disease progression.63,64 However, in our meta-analysis of proportions, we did not detect a signal of benefit of APP in the subgroup of subjects with 
/
ratio > 150 mm Hg. Third, the duration of APP might have a dose-response relationship, and it is possible that a reduction in the rate of intubations could be seen only in subjects who were subjected to longer periods of APP. Our subgroup analyses did not demonstrate significantly lower intubation rates for subjects who remained in PP for longer periods of time, but it could be argued that our analysis was underpowered, as only 2 studies (n = 65) reported daily APP periods > 16 h.9,36 Fourth, intubation might be inevitable as the disease progresses, despite initial and sustained improvement in oxygenation. It has been argued that intubation rates are lower in patients who experience sustained improvement in oxygenation after APP, the so-called responders.35 However, this finding has not been replicated in other retrospective studies11 and could be the result of simple reverse causality, with patients responding to APP because of their already favorable clinical course. Finally, an unknown proportion of subjects with do-not-intubate orders was included in both groups, which could have diluted any possible benefit of APP.
We did not demonstrate a signal of reduced mortality with APP. Given the complex relationship between disease severity, individual comorbidities, socioeconomic status, and variable access to quality care during a pandemic, this finding should be interpreted as exploratory. Due to the retrospective nature of included studies, selection biases are very likely. The type of respiratory support (conventional oxygen therapy, HFNC, CPAP/NIV delivered through a conventional mask vs a helmet) was not balanced between subjects treated with APP and those who were not. Analyses with stratification by the type of respiratory support device did not demonstrate significant subgroup differences in mortality. These subgroup analyses were severely limited by the fact that we only included observational studies in our analysis; had access only to overall group statistics, not individual patient data; and a proportion of subjects were treated with various devices through the course of their disease.
Our study has several limitations. First, data were available only from a group of relatively heterogeneous observational studies. Significant levels of inclusion bias are also likely to be present. Without individual patient data, we could not account for the many uncontrolled differences between subjects treated with APP and those who received usual care. Some subjects were subjected to APP in extremis after failing usual care and could have been sicker than subjects included in cohorts without APP. Conversely, in other reports, only subjects who could self-prone were treated with APP, and these were likely less sick than those in the control group. Second, a variety of respiratory support devices, including helmet CPAP, was used in both groups. It is not known whether the choice of the device has an impact on outcomes in patients with severe COVID-19. Third, outcomes were highly heterogeneous, which likely reflects populations with various disease severities, various comorbid conditions, as well as geographical variations of care for patients with ARDS.65 Fourth, we included unpublished, non-peer-reviewed data. However, our findings remained robust with the exclusion of unpublished data. Fifth, the mortality rate in our studies is lower than reported in other large cohorts,66-68 which suggests selection and publication bias, which would be expected to be in favor of APP. Sixth, we were not able to control for the use of evidence-based treatments such as corticosteroids. However, all included reports finished enrollment before the benefit of corticosteroids was demonstrated69 and when their use was indeed actively discouraged. Seventh, only a minority of subjects were able to tolerate longer periods of APP, and it can be argued that the duration of APP was not sufficient to generate a clinically meaningful change in outcomes. However, a physiologically effective but clinically intolerable intervention would remain ineffective overall. Eighth, data for other important outcomes, such as the number of ventilator-free days or the ICU length of stay, were not available for analysis. Finally, all included studies were performed during the initial months of the pandemic. At that time, most groups were not experienced with APP. We may imagine that APP would be more effective after the learning period when patient selection, positioning, monitoring, and duration of session are more established. Most of these subjects were infected with the initial virus. The efficacy of APP may be different in variants, and the effect of APP may be higher as clinicians gain experience with this technique.
Conclusions
In summary, available evidence from observational studies suggests that APP improves oxygenation, but these improvements do not appear to translate into reduced rates of intubation at the first wave of pandemic real-world practice. We did not find any obvious signals of harm, and we did not see any worrisome signal in mortality. The high selectivity of subjects, the inconsistency in the application of prone positioning in published reports, and the heterogeneity of outcomes emphasize the need for randomized controlled trials, as a clinically important benefit cannot be excluded based on available low-quality data. Given the promising benefit of APP on intubation, trials should endeavor to include patients with different disease severity, managed with a uniform strategy of respiratory support, and with clear criteria for intubation.
Footnotes
- Correspondence: Jie Li PhD RRT RRT-ACCS RRT-NPS FAARC. Email: Jie_Li{at}rush.edu
Dr Li discloses relationships with Fisher & Paykel Healthcare, Aerogen, The Rice Foundation, and the American Association for Respiratory Care. She also serves as Section Editor for Respiratory Care. Drs Pavlov, Ehrmann, and Perez disclose relationships with Fisher & Paykel Healthcare. Dr Roca discloses relationships with Hamilton Medical and Air Liquide. Dr Laffey discloses a relationship with Baxter Healthcare; Dr Ehrmann discloses relationships with Fisher & Paykel Healthcare, La Diffusion Technique Française, Aerogen, and Hamilton Medical. Ms Jackson and Dr Trump disclose relationships with Fisher & Paykel Healthcare. Dr Rubin is the president of DRDR Mobile Health, a company that creates mobile applications for health care, including functional capacity assessment applications. Dr Vines discloses relationships with Ohio Medical, Theravance Biopharma, Teleflex Medical, and The Rice Foundation. The remaining authors disclose no conflicts of interest.
This work was supported by OpenAI and The Rice Foundation. The funding bodies had no role in the design of the study, in collection, analysis, and interpretation of data, nor in writing of the manuscript.
Drs Pavolv, He, McNicholas, and Perez are co-first authors.
Supplementary material related to this paper is available at http://www.rcjournal.com.
- Copyright © 2022 by Daedalus Enterprises
References
